Data compiled by Redley Lamar · ChainSifter Intelligence
0Suppliers
9Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
bioAffinity Technologies, Inc. (BIAF) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
13Total relationships
2Distinct source URLs
9High confidence
0.822Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
bioAffinity Technologies, Inc. Suppliers
No suppliers on recordbioAffinity Technologies, Inc. has not yet been matched to upstream suppliers in our database, or is still being processed.
bioAffinity Technologies, Inc. Customers
Ticker
Name
Confidence
Evidence
CONTRACT-RESEARCH-ORGANIZATIONS
CONTRACT-RESEARCH-ORGANIZATIONS
90%
The Company's other customer types include contract research organizations ("CRO's), hospitals, and independent laboratories.
HOSPITALS
HOSPITALS
90%
The Company's other customer types include contract research organizations ("CRO's), hospitals, and independent laboratories.
INDEPENDENT-LABORATORIES
INDEPENDENT-LABORATORIES
90%
The Company's other customer types include contract research organizations ("CRO's), hospitals, and independent laboratories.
GOVERNMENTAL-PAYORS
GOVERNMENTAL-PAYORS
85%
Furthermore, in addition to its contracts with patients, the Company separately contracts with third-party payors (insurance companies and governmental payors), who are typically responsible for all …
INSURANCE-COMPANIES
INSURANCE-COMPANIES
85%
Furthermore, in addition to its contracts with patients, the Company separately contracts with third-party payors (insurance companies and governmental payors), who are typically responsible for all …
Reciprocal relationship from MYGN graph: Reciprocal relationship from BIAF graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from BIAF graph: Reciprocal relationship from MYGN g…
ddition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent’s claims narrowly, or refuse to stop the o…
EMERGING-GROWTH-COMPANY
EMERGING-GROWTH-COMPANY
62%
d process, which considers historical denial and collection experience and other factors (including the period of time that the receivables have been outstanding), to estimate contractual allowances …
THERAPEUTICS-LLC
THERAPEUTICS-LLC
62%
the foreseeable future. As a result, the Company had an accumulated deficit of $ 68.6 million at December 31, 2025. The Company’s cash and cash equivalents at December 31, 2025, were approximately $ …
bioAffinity Technologies, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
BIAF-DEBT-8187
Warrants outstanding: 2317607
90%
xbrl warrant detail from xbrl 2026-03-31.
BIAF-DEBT-8188
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2022-12-31.
BIAF-DEBT
Debt stack $1.2M
90%
Market cache reports total debt of $1.2M.
bioAffinity Technologies, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for bioAffinity Technologies, Inc..
bioAffinity Technologies, Inc. Ownership
Holder
Name
Confidence
Evidence
BIAF-OWNER-BARCLAYS-PLC
BARCLAYS PLC
90%
13F overlay lists BARCLAYS PLC as top holder; 1 tracked holders.
bioAffinity Technologies, Inc. Extended Supply Chain Network
